uniQureQURE
Recorded

uniQure 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration49 minParticipants19

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Hello, and thank you for standing by. My name is John, and I will be your conference operator today. At this time, I would like to welcome everyone to the uniQure third quarter 2026 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press star followed by the number 1 on your telephone keypad. If you would like to withdraw your question, press star one again. Thank you. I would now like to turn the call over to Chiara Russo, Senior Director of Investor Relations.

Chiara RussoSenior Director of Investor Relations

Thank you. Good morning, and thank you for joining us for uniQure's third quarter of 2026 earnings call. Earlier this morning, uniQure released its financial results for the third quarter of 2026, and our press release is available on the investors and media section of our website at uniQure.com. Our 10-Q was also filed with the SEC earlier today. Joining me on the call this morning are Matt Kapusta, Chief Executive Officer, Dr. Walid Abi-Saab, Chief Medical Officer, Kylie O'Keefe, Chief Customer and Strategy Officer, and Christian Klemt, Chief Financial Officer. After our formal remarks, we'll open up for an analyst Q&A. Before we begin, please know that we'll be making forward-looking statements during this investor call. All statements other than statements of historical fact are forward-looking statements.

Chiara RussoSenior Director of Investor Relations

They are based on management's beliefs and assumptions and on information available to management only as of the date of this conference call. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including without limitation the factors described in uniQure's most recent SEC filing. Given these risks, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these statements even if information becomes available in the future. Now, let me introduce Matt Kapusta, uniQure's CEO.

Matt KapustaCEO

Thanks, Chiara. Good morning, and thank you for joining us on today's call. For the families who await generations for a treatment for Huntington's disease, this quarter brought meaningful progress. As we announced Monday, the FDA has accepted our Biologics License Application for AMT-130 and granted Priority Review with a target PDUFA date of May 1st, 2027. In the U.K., the MHRA has also validated our Marketing Authorization Application. These are the first such marketing applications for disease-modifying therapy for Huntington's disease, and it brings patients and families one step closer to a treatment option. We greatly appreciate the engagement of both the FDA and the MHRA and their focus on the critical need for new therapies in Huntington's disease. I also want to acknowledge the commitment of our clinical, regulatory, and CMC teams who prepared and submitted both applications in record time.

Matt KapustaCEO

To every HD patient, family member, and investigator who has trusted us with their hope, thank you. In September, we shared additional data from our ongoing phase I/II studies, including updated 36-month data from all 27 evaluable patients across the low and high-dose cohorts, and for the first time, 48 months of follow-up after a single administration of AMT-130. These data continue to show meaningful dose-dependent slowing of disease progression and reinforce our strong belief that AMT-130 has the potential to deliver treatment benefit to patients. We are also pleased to have aligned with the FDA on the key elements of the confirmatory study design, and we are making significant progress getting the trial up and running. We are fully committed to the timely execution of this study, and our priority is to have it well underway at the time of an approval decision.

Matt KapustaCEO

Walid will provide more detail on the confirmatory study later in the call. Regarding commercial preparations, we are making excellent progress ahead of potential U.S. launch in 2027. We continue to build out our field, medical, market access, and strategic account teams in a disciplined way, and our financial strength provides the runway needed to execute this build-out. Kylie and Christian will provide more details on our commercial readiness and financial position later on the call. Beyond AMT-130, we continue to advance our broader pipeline. We have completed enrollment in the second dose cohort of our phase I/IIa study of AMT-260 in refractory mesial temporal lobe epilepsy and have resumed enrollment in the phase I/II study of AMT-191 in Fabry disease. For both programs, we expect to present new and updated data in the first half of 2027. In summary, we are heading into the end of 2026 with strong momentum.

Matt KapustaCEO

Our priorities are clear: working closely with regulators as the application reviews proceed, executing our confirmatory study, advancing our pipeline, and building the organization to prepare for the planned launch of AMT-130. With that, I will turn the call over to Walid to provide additional detail on AMT-130 and our pipeline.

Walid Abi-SaabChief Medical Officer

Walid? Thank you, Matt. Good morning and good afternoon, everyone.

Walid Abi-SaabChief Medical Officer

I will start with AMT-130 in Huntington's disease, or HD. As Matt noted, the BLA is under Priority Review with a PDUFA date of May 1, 2027, and the MAA has been validated by the MHRA. Both submissions are based on the 36-month analysis we presented in September 2025. In that analysis, the high dose of AMT-130 showed a 75% slowing of disease progression on the composite Unified Huntington's Disease Rating Scale, or cUHDRS, and a 60% slowing on Total Functional Capacity, or TFC, compared with a propensity score-matched external control. Both results were statistically significant. With the BLA now accepted and under active review, going forward, we will not be commenting on specific information requests made by the FDA, including questions regarding a potential AdCom. The FDA indicated that they are tentatively planning to discuss our application at an AdCom.

Walid Abi-SaabChief Medical Officer

As you are aware, scheduling an AdCom is within the sole discretion of the agency. In September 2026, we presented detailed analyses from a recent data cutoff. I will not repeat that today. Instead, I would like to focus on the progress we have made towards initiating the confirmatory study. Earlier this year, we reached alignment with the FDA on key elements of the design. Specifically, this will be a randomized study with a 2:1 ratio of AMT-130 high dose to standard of care. It will include approximately 200 patients. The primary endpoint is TFC at 36 months. After 36 months, all standard of care participants will be offered AMT-130 in a separate open-label study. uniQure is fully committed to completing the study in a timely manner. Preparations started at the beginning of this year and have accelerated following alignment with the FDA.

Walid Abi-SaabChief Medical Officer

This will be a global study with sites across North America, Europe, and Latin America. The protocol has already been submitted to institutional review boards, or IRBs, in the U.S., and we expect to begin patient screening by the end of this year. I would like to take a moment to talk about TFC, the primary endpoint in the confirmatory study. This is a clinical endpoint that is very important not only for regulators, but also for people living with HD. Why is TFC important? TFC captures whether a person can keep working, manage their finances, handle household responsibilities, take care of themselves day-to-day, and live without full-time care. For patients and families, these are not abstract measures. They are the difference between maintaining and losing independence, and they are directly related to quality of life. This is what patients and families care about.

Walid Abi-SaabChief Medical Officer

In fact, it is what we heard from HD specialists at the two most recent scientific meetings we attended, the International Parkinson and Movement Disorder Society meeting in Seoul and the European Huntington's Disease Network meeting in Kraków. These specialists described TFC as the endpoint they find most meaningful when talking with patients. Across our phase I/II studies, TFC declined by less than a tenth of a point per year in patients who received the high dose of AMT-130. This remarkably slow decline was consistent across all analyses and maintained through four years following treatment. Although these results come from a relatively small number of patients, they have never been seen before in HD. Moving on to our other clinical programs, starting with AMT-260 for refractory mesial temporal lobe epilepsy.

Walid Abi-SaabChief Medical Officer

Following the initial six-month data of the first low-dose cohort of six patients, which was presented in June, earlier this quarter, we completed enrollment of the second cohort of seven higher-dose patients. We expect to present updated results from both cohorts in the phase I/IIa study in the first half of 2027. Turning to AMT-191 for Fabry disease. In August, enrollment resumed in the mid and high-dose cohorts. As a reminder, dosing has been paused per protocol in these two cohorts after asymptomatic liver enzyme elevations, which fully resolved following a course of immunosuppression. We presented updated results in June from a March 15th cutoff, and we expect to share updated results from all three dosing cohorts in the first half of 2027. Now, I will turn the call over to Kylie to discuss our recent patient advocacy work.

Kylie O’KeefeChief Customer and Strategy Officer

Kylie? Thanks, Walid. With the known PDUFA date ahead of us, the question for our customer-facing team is no longer when, it's how.

Kylie O’KeefeChief Customer and Strategy Officer

How do we make sure every piece of this patient journey is in place and well-supported by the PDUFA date, so if approval is granted, we are ready to launch? For AMT-130, that journey runs from identifying an eligible patient through evaluation, surgery, follow-up, and reimbursement. It involves many critical stakeholders. Our job is to ensure a smooth process for patients, families, and the clinicians who care for them. For many of these families, the patient journey already runs through a familiar place, a specialty HD clinic they have relied on for years. That is an important feature of this market, as HD care is concentrated. A large share of diagnosed patients are seen at a number of specialty centers, many of them HDSA Centers of Excellence.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day